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Abstract
Introduction: In autoimmune diseases, IL-17 producing T-cells (Th17), a pro-inflammatory subset of T-cells, are
pathophysiologically involved. There is little knowledge on the role of Th17 cells in granulomatosis with
polyangiitis (GPA). In the present study, we investigated Th17 cells, Tregs and subsets of circulating Th17 cells in
GPA and related results to disease activity.
Methods: 42 GPA patients in remission, 18 with active disease and 14 healthy controls (HC) were enrolled. Th17
cells, their subsets and regulatory T-cells were determined by intracellular fluorescence activated cell sorter (FACS).
Data are given as mean percentage ±SD of total T-helper-cells.
Results: Th17 cells are expanded in active and quiescent GPA as compared to HC (1.7±1.4% vs. 0.7 ±0.3%, P =
0.006 and 1.9 ± 1.5% vs. 0.7 ± 0.3%, P < 0.0001). Th17 expansion is stable over time and does not decline when
remission is achieved. However, a negative association of Th17 cells and steroid dosage is observed (r = -0.46, P =
0.002). The Th17 expansion was not balanced by Tregs as indicated by skewed Th17/Treg ratios in active and
quiescent GPA. Th17 subsets co-producing IFNg or IL-10 are significantly increased in GPA. GPA patients in
remission not receiving maintenance therapy have significantly more IL-10/IL-17A double positive T-cells than HC
(0.0501 ± 0.031% vs. 0.0282 ± 0.016%, P = 0.007).
Conclusions: We provide evidence for a persistent, unbalanced expansion of Th17 cells and Th17 subsets which
seems to be independent of disease activity. Maintenance therapy reduces -but does not normalize- Th17
expansion.
Introduction
Granulomatosis with polyangiitis (GPA) is an autoimmune
form of necrotizing small-vessel vasculitis characterized by
the presence of antineutrophil cytoplasmic antibodies
(ANCA). GPA is strongly associated with ANCA directed
against proteinase-3 (PR3) and in a minority of cases,
ANCA with specificity for myeloperoxidase (MPO) are
detected [1-3]. Alongside the role of the autoantibodies in
disease pathogenesis, T cells also contribute to disease
mechanisms as suggested by the isotype of ANCA, which
indicates that a T cell-dependent class-switch has taken
place [4]. Furthermore, T cells are present in inflammatory
lesions related to GPA and it is thought that granuloma
formation in GPA is T cell-dependent [5-7]. Accordingly,
deviation of circulating T cells has been described in GPA
showing persistent T cell activation, expansion of memory
T cells and a deficient function of regulatory T cells [8-14].
Th17 cells were recently described as a separate
T-helper-cell lineage with distinct features [15,16]. IL-
17A is a signature cytokine of this T-helper-cell lineage.
IL-17A drives inflammation by promoting neutrophil/
macrophage recruitment, enhances auto-antibody pro-
duction and facilitates tissue destruction by upregulation
of matrix metalloproteases [17,18]. A role for Th17 cells
has been established in autoimmune diseases such as
giant cell arteritis (GCA), rheumatoid arthritis (RA) and
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systemic lupus erythematosus (SLE) [17,19-22]. In these
diseases, increased circulating Th17 cells have been clo-
sely associated to disease activity.
Also in GPA, a pathogenic role of Th17 cells is likely.
Gan et al. showed in an animal model of experimental
MPO-vasculitis that IL-17A deficiency attenuated the
disease [23]. In addition, the frequency of auto-antigen-
specific Th17 cells in convalescent ANCA-vasculitis is
increased [24,25]. Another study by Fagin et al. showed
that auto-antigen-specific Th17 cells, including IL-17A/
IFNg and IL-17A/IL-4 double producers, were also
increased in active ANCA-vasculitis [26]. The role of
auto-antigen-specific T cells in the initiation of autoim-
munity is controversial. Ghani et al. found that antigen-
specific T cells condition inflamed sites for high-rate
antigen non-specific effector T cell recruitment [27]. In
contrast, Murakami et al. recently reported that antigen
specificity is of limited importance to initiate autoim-
mune processes [28]. In an experimental mouse model,
activated Th17 cells were able to initiate arthritis in the
absence of cognate antigen recognition [28]. Since com-
parable non-antigen-dependent mechanisms might be
operative in GPA, we investigated 1) the presence of cir-
culating Th17 cells in active and quiescent GPA, 2)
whether Th17 expansion is balanced by regulatory T-cell
subsets, and 3) concomitant expression of different cyto-
kines in Th17 cells.
Materials and methods
Patient cohort
We enrolled 60 patients with GPA, (12 with MPO-ANCA,
48 with PR3-ANCA, Table 1), mean age (± SD) 57 (± 13)
years, and 14 age-matched healthy volunteers (healthy
controls, HC), mean age 53 ± 5 years. Eighteen patients
were in an active state of disease at presentation and forty-
two were in remission (Table 1, 2). Informed patient con-
sent and approval by the local ethics committee was
obtained. Seven patients initially presenting with active
disease were assessed again after remission was achieved.
The diagnosis and classification of GPA was made accord-
ing to criteria of the American College of Rheumatology,
the Chapel Hill criteria and the algorithm published by
Watts et al. [29-31]. Active disease was defined as clinical
manifestation of new-onset or recurrent disease activity
related to vasculitis requiring intensified immunosuppres-
sive therapy [32,33]. All patients with active disease were
either untreated or treated with maintenance therapy at
the time of sampling. None of the active patients had
received cyclophosphamide or high dose intravenous
methylprednisolone at the time of sampling. Remission or
quiescent disease was defined as absence of clinical disease
activity reflecting a Birmingham Vasculitis Activity Score
of zero [33]. The cohort of patients in remission was
divided for further analysis into two groups: patients in
long-term stable remission, and patients with a relapsing
disease course. Patients with a relapse-free disease course
since the first onset of GPA and a minimum disease dura-
tion of 48 months, were defined as being in stable long-
term remission (n = 13). Patients with a minimum disease
duration of 48 months and at least one relapse within the
first 48 months since diagnosis of GPA were defined as
relapsers (n = 19).
Flow cytometry: staining of surface antigens
Lymphocyte phenotypes were measured by five-colour
surface staining. The following antibodies labeled with
fluorescent dye were used: CD3 (mouse IgG1, HorV450),
CD4 (mouse IgG1, PerCP; ITK/Biolegend, Uithoorn, The
Netherlands), CD8 (mouse IgG1, APC-H7), CD25 (mouse
IgG1, FITC), CD127 (mouse IgG1, PE). All antibodies
except CD4 were purchased at BD Bioscience, Breda, The
Netherlands. Appropriate isotype controls (BD Bioscience)
were used. Peripheral blood mononuclear cells (PBMC)
were isolated by standard Ficoll density gradient centrifu-
gation (Histopaque; Sigma Aldrich, Zwijndrecht, The
Netherlands) and incubated with labeled monoclonal anti-
bodies for 30 minutes in the dark at room temperature.
Analysis was performed with a fluorescence-activated cell
sorter (FACS) CANTO™ from BD Bioscience.
Immunostaining for intracellular cytokines
PBMC from patients and HC were separated by standard
Ficoll density gradient centrifugation. The cells were
resuspended in RPMI 1640 medium (Gibco Invitrogen,
Table 1 Clinical characteristics of the patient cohort
Characteristic Remission Active disease
Number 42 18
Age, years, mean ± SD 58 ± 13 54 ± 14
PR3/MPO 37/5 11/7
Disease duration, months, mean ± SD 105 ± 75 67 ± 97
Treatment, yes/no 16/26 7/11
Steroids, yes/no 13/3 (12 patients: 5 to 10 mg; 1 patient: 30 mg) 7/0 (4 patients: 5 to 10 mg; to 45 mg)
AZA/MMF/MTX/CYC 7/2/4/0 2/1/0/0
PR3/MPO, proteinase-3/myeloperoxidase (describes the anti-neutrophil-cytoplasmic antibodies specificity at the time of diagnosis); AZA, azathioprine; CYC,
cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate.
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Breda, The Netherlands) supplemented with 10% heat-
inactivated fetal calf serum (Greiner Bio-One, Alphen a/d
Rijn, The Netherlands), 100 U/mL penicillin and 100 µg/
mL Streptomycin (both Gibco Invitrogen). The cells were
cultured in the absence or presence of PMA (50ng/mL)
and Ionomycin (1µg/mL) (Sigma-Aldrich) for 4 hours.
Cytokine secretion was inhibited by Brefeldin A (BD
Bioscience). Surface staining was performed with CD3
HorV450 and CD8 APC-H7 (both BD Bioscience). Cells
were fixed using a Cytofix/Cytoperm kit (BD Bioscience).
Finally, the samples were stained intracellularly for CD69
(ITK/Biolegend), IFNg (BD Bioscience), IL-4, IL-10
and IL-17A (all ITK/Biolegend). Unstimulated PBMC
and appropriate isotype controls were used to confirm
specificity of staining and to discriminate background
staining. FSC-H vs. FSC-A gating allowed exclusion of
cell doublets. As stimulation with PMA/ionomycin
induced downregulation of CD4, CD4+ T cells were
defined as CD3+CD8neg, and an average of 30,000 events
was acquired in this CD3+CD8neg gate. CD69 expression
was used as a control for the activation procedure but
was not included in the gating strategy. CD69 expression
did not differ between HC and patients with GPA after
mitogen stimulation (94.97 ± 3.49% vs. 95.25 ± 3.54%,
P > 0.05).
Statistics
All values are expressed as mean ± SD. Significance for
the differences between groups was determined using the
Mann-Whitney U-test. Spearman’s rank correlation test
was applied to detect correlation between different study
parameters.
Results
Circulating Th17 cells are increased during active disease
and remain elevated during remission
Patients with active GPA (n = 18) showed a significantly
increased percentage of circulating IL-17A+ T cells com-
pared to HC (n = 14) (% of CD4+ T cells = 1.7 ± 1.4% vs.
0.7 ±0.3%, P = 0.006 (Figure 1A, B), while there was no
difference in IFNg (14.5 ± 9.9% vs. 17.7 ± 7.9%, P = 0.17),
or IL-4-producing CD4+ T cells (5.6 ± 3.3% vs. 4.9 ±
2.1%, P = 0.7). There were no significant differences
between active patients with or without maintenance
therapy at the time of sampling.
Th17 expansion was similar between active GPA and
quiescent GPA (n = 42, 1.7 ± 1.4% vs. 1.9 ± 1.5%, P =
0.37 (Figure 1B). Seven patients first assessed during the
active state of disease were sampled again during remis-
sion (median time between visits 118 days, range 71 to
567 days). The percentage of Th17 cells did not decline
during remission (Figure 1C).
Accordingly, circulating IL-17A+ T cells were elevated in
GPA patients in remission compared to HC (% of CD4+
T cells = 1.9 ± 1.5% vs. 0.7 ± 0.3%, P < 0.0001) (Figure 1A,
B) whereas IFNg (22.1 ± 10.8% vs. 17.7 ± 7.9%, P = 0.20),
and IL-4 producing-T-helper-cells (6.1 ± 2.5% vs. 4.9 ±
2.1%, P = 0.11) did not differ between patients with GPA
and the HC. Of note, IFNg+ T-cells were significantly
reduced in patients with active GPA compared to those
Table 2 Characteristics of patients with active disease at the time of sampling
Patient number Age (years) ANCA type Disease duration (months) Disease activity at time of sampling BVAS CRP (mg/L)
1 55 PR3 0 A, ENT, K, L 25 292
2 37 PR3 44 A, ENT 5 20
3 55 PR3 57 A, K, L 15 247
4 58 MPO 120 A, L 7 23
5 49 PR3 190 A, ENT, L 10 46
6 57 PR3 259 Ey, ENT 6 < 5
7 56 PR3 191 Ey 6 < 5
8 82 MPO 0 L 4 44
9 53 PR3 0 A, ENT, K, L 17 160
10 74 PR3 0 K 10 NA
11 69 PR3 9 ENT, K 14 211
12 41 MPO 0 A, ENT, K, S 17 44
13 58 MPO 0 ENT, K, S 14 116
14 70 MPO 0 A, ENT, K, L 19 188
15 53 PR3 15 Ey, K 12 12
16 24 PR3 9 A, Ey 3 16
17 40 MPO 33 ENT 6 < 5
18 41 MPO 284 K, L 12 < 5
None of the patients received induction therapy at the time of sampling. PR3/MPO, proteinase-3/myeloperoxidase; this reflects anti-neutrophil-cytoplasmic
antibodies specificity (ANCA) at the time of diagnosis. Organ involvement of patients with active disease at the time of sampling is depicted. A, arthritis (joints);
BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ENT, ear-nose-throat; Ey, ophthalmologic manifestation of disease; K, kidney; L, lung; S, skin.
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with quiescent disease (14.5 ± 9.9% vs. 22.1 ± 10.8%, P =
0.002).
CD3+CD4negCD8neg (DN) T-cells were previously
described as producers of IL-17 [34]. However, there
was no difference between HC and patients with GPA
in the percentage of DN T cells (% of CD3+ T-cells in
the HC vs. quiescent GPA = 2.9 ± 2.0% vs. 3.1 ± 2.9%,
P > 0.05, and in the HC vs. active GPA = 2.9 ± 2.0% vs.
3.4 ± 4.1%, P > 0.05). Moreover, DN T cells did not
correlate with Th17 cells (r = -0.4, P = 0.2 in the HC;
r = -0.3, P = 0.3 in patients with GPA).
Clinical associations with Th17 cells in GPA
ANCA-status, that is, PR3/MPO-ANCA negative (n =
12) vs. positive (n = 30) at the time of sampling, did not
have impact on the percentage of Th17 cells (data not
shown). Patients with (n = 16) or without maintenance
(n = 26) therapy both had a significant increase of Th17
Figure 1 Th17 cells in cross-sectional and longitudinal analysis. (A) Representative fluorescence activated cell sorter (FACS) plots of a
volunteer healthy control (HC) and a patient with granulomatosis with polyangiitis (GPA). Plots are gated on CD3+CD8neg T cells and 40,000
events are shown in each graph. (B) The percentage of Th17 cells was higher in quiescent GPA than in HC. Active GPA patients showed a
significantly increased Th17 cell fraction compared to HC and did not differ from quiescent GPA. Mean values are indicated by the horizontal
line, and error bars represent the SD. (C) Seven patients were first assessed during the active phase of disease and then again after remission
had been achieved. The dotted line represents the mean value in the HC. *P < 0.05, **P < 0.005.
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cells compared to the HC (1.33 ± 0.94% vs. 0.7 ± 0.3%,
P = 0.03 and 2.32 ± 1.61% vs. 0.7 ± 0.3%, P < 0.0001).
However, patients on maintenance therapy harbored a
significantly smaller fraction of Th17 cells than
untreated patients (1.33 ± 0.94% vs. 2.32 ± 1.61%, P =
0.01).
In addition, administration of steroids had an impact
on Th17 cells as there was a negative correlation of ster-
oid dosage and percentage of Th17 cells (r = -0.46, P =
0.002). A similar effect was observed for Th1 cells and
steroid dosage (r = -0.32, P = 0.04), and so a separate
analysis accounting for maintenance therapy was also
performed. To assess the impact of Th17 cells on the
clinical course of the disease, we stratified the patient
cohort into relapse-free and relapsing patients, and iden-
tified 13 relapse-free patients and 19 relapsing patients.
Two relapse-free patients and nine relapsing patients
received maintenance treatment at the time of sampling.
As shown before, treatment seemed to have impact on
the percentage of Th17 cells. Therefore, we compared
untreated relapsing patients in remission (n = 10) with
untreated relapse-free patients in remission (n = 11).
Th17 cells were similar between both groups (% Th17
cells = 2.3 ± 1.0% vs. 2.6 ± 2.2%, P = 0.7).
Disturbed balance of circulating Th17 cells and regulatory
T cells in active and quiescent GPA
Regulatory T-helper-cell subsets control and limit immune
responses of pro-inflammatory T cells. In this study, we
focused on two types of regulatory T cells (Tregs), which
were defined according to literature: CD4+CD25highC-
D127low Tregs and IL-10+ Tregs [35,36]. CD4+CD25highC-
D127low Tregs were increased in quiescent GPA (8.3 ±
3.5% in untreated patients, n = 22; 6.0 ± 1.1% in treated
patients, n = 13) and active GPA (7.0 ± 2.8%, n = 18) com-
pared to the HC (5.1 ± 1.0%, n = 13)(P < 0.006, P = 0.06,
and P = 0.02 respectively, for comparison with the HC)
(Figure 2A). In contrast, IL-10+ Tregs did not differ
between quiescent GPA (0.7 ± 0.4% in untreated patients,
n = 26; 0.5 ± 0.2% in treated patients, n = 16) or active
GPA (0.6 ± 0.4%, n = 17) compared to the HC (0.5 ± 0.3%,
n = 14) (P = 0.13, P = 0.7, and P = 0.52 respectively, for
comparison with the HC) (Figure 2A). As Th17 cells and
Treg share developmental pathways, a reciprocal relation-
ship has been described [37]. Accordingly, Th17 expansion
is associated with Treg depletion in human SLE [22].
Therefore, a correlation analysis was performed to assess
the Th17/Treg relationship in GPA. Th17 cells were posi-
tively correlated with CD4+CD25highCD127low or IL-10+
Tregs in quiescent GPA (r = 0.34, P < 0.05 and r = 0.38,
P = 0.01) and active GPA (r = 0.36, P = 0.14 and r = 0.60,
P = 0.01) but not in the HC (r = -0.04, P = 0.90 and r =
0.19, P = 0.52). Separate analysis of GPA patients in remis-
sion stratified by maintenance treatment showed only a
significant positive correlation between IL-10+ Tregs and
Th17 in patients on maintenance therapy (r = 0.68, P =
0.004). Thus, a reciprocal relationship or a negative asso-
ciation between Th17 cells and Tregs was not found.
Ratios were calculated to assess if the balance between
Th17 cells and Tregs was preserved in GPA. Importantly,
Th17 expansion was not balanced by Tregs in quiescent,
untreated GPA and active GPA indicated by both a
higher Th17/CD25highCD127low Treg ratio and Th17/IL-
10+ Treg ratio compared to HC (Figure 2B). Interestingly,
in quiescent, treated GPA, only the Th17/IL-10+ Treg
ratio was significantly skewed towards Th17, whereas the
Th17/ CD25highCD127low Treg ratio was not different
from HC (Figure 2B). Relapsing and relapse-free patients
had comparable Th17/Treg ratios, with 0.36 ± 0.32 vs.
0.39 ± 0.38 (P = 1.0) for Th17/CD25highCD127low Treg,
and 4.9 ± 2.8 vs. 4.3 ± 3.8 (P = 0.6) for Th17/IL-10+ Treg.
Th17 cells co-expressing IL-10 or IFNg are elevated in
active GPA and untreated quiescent disease
IFNg and IL-10 co-expression of Th17 cells was mea-
sured in a subset of GPA patients. Both IL-10+/IL-17A+
and IFNg+/IL-17A+ CD4+ T cells could be detected in
GPA and HC. The percentage of IL-10+/IL-17A+ CD4+ T
cells was higher in untreated quiescent GPA (0.0501 ±
0.031%, n = 23), but not in treated quiescent GPA
(0.0432 ± 0.053%, n = 15), than in the HC (0.0282 ±
0.016%, n = 14) (P = 0.007 and P = 0.91 respectively, for
comparison with the HC) (Figure 3A).
In active GPA, the percentage of the IL-10+/IL-17A+
population (0.0703 ± 0.076%, n = 12) did not differ from
the HC (0.0282 ± 0.016%, n = 14, P > 0.05) (Figure 3A).
IFNg+/IL-17A+CD4+ T cells were significantly increased
in untreated, quiescent GPA (0.24 ± 0.18%, n = 24, P =
0.001), but not in treated, quiescent GPA (0.20 ± 0.18%,
n = 15, P = 0.09), and in active GPA (0.19 ± 0.19%, n = 12,
P < 0.05) compared to the HC (0.09 ± 0.07%, n = 14)
(Figures 3B and 3C). IFNg+/IL-10+ T cells did not differ
between the patients and HC (data not shown). Thus,
Th17 cells producing IL-10 or IFNg were increased only in
untreated, quiescent and active GPA.
Discussion
In patients with GPA, we observed Th17 expansion, and
demonstrated that Th17 expansion is present during
active disease and persists after remission has been
achieved. Th17 cells seemed to be sensitive to mainte-
nance treatment but remained elevated. Th17 expansion
was not balanced either by CD25highCD127low, or by IL-
10+ Tregs. Finally, we observed an elevated percentage
of Th17 cells expressing IL-10 or IFNg in untreated
GPA, which possibly indicates enhanced plasticity.
Antigen-specific Th17 expansion has previously been
reported in GPA [24,26,38]. The role of antigen-specific
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T-cells in initiation of tissue inflammation is controver-
sial. According to Ghani et al., antigen-specific T-cells
are crucial initiators of tissue inflammation, whereas a
recent publication by Murakami et al. suggests that anti-
gen specificity of Th17 cells is of limited importance for
the initiation of autoimmune processes [27,28]. There-
fore, both auto-antigen-specific and, as determined in
our study, non-specific Th17 expansion may be relevant
in GPA. The driving force of Th17 cell expansion
remains unclear; chronic challenge with auto-antigen or
deficient function of Tregs seems likely [24,25,39]. Alter-
natively, high levels of cytokines promoting Th17 polari-
zation could be an underlying cause. In line with this,
increased levels of the Th17 enhancing cytokines TGFb,
IL-6 and IL-23 can be found in the sera of GPA [24,40].
DN T-cells have been recently described as one major
source of IL-17 and seem to be expanded in SLE [34].
However, in GPA patients, levels of DN T-cells
Figure 2 Regulatory T cells (Tregs) are expanded in granulomatosis with polyangiitis (GPA) but do not balance Th17 skewing. (A) The
percentage of IL-10+ Tregs was similar in active/quiescent GPA vs. healthy controls (HC), whereas CD25highCD127low Tregs were significantly
increased. (B) The Th17/IL-10+ Treg ratio was significantly increased in quiescent untreated GPA (4.18 ± 3.07, P = 0.001, n = 26), quiescent
treated GPA (2.67 ± 1.34, P = 0.02, n = 16) and active GPA (2.97 ± 1.63, P = 0.04, n = 17) vs. HC (1.75 ± 1.30, n = 14). The Th17/
CD25highCD127low Treg ratio was higher in quiescent, untreated GPA (0.33 ± 0.31, P = 0.008, n = 22) and in active GPA (0.25 ± 0.19, P = 0.04,
n = 18), but not in quiescent, treated GPA (0.21 ± 0.18, P = 0.54, n = 13) compared to HC (0.14 ± 0.07, n = 13). Bars represent means, error bars
indicate the SD. *P < 0.05, **P < 0.006.
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Figure 3 Th17 cell subsets are increased in granulomatosis with polyangiitis (GPA). (A) IL-17+IL-10+ CD4+ T cells were increased in
quiescent, untreated GPA compared to quiescent, treated GPA and healthy controls (HC). No difference was detected between HC and patients
with active GPA. (B) IFNg producing Th17 cells were increased in quiescent, untreated GPA and active GPA compared to HC. Means are
indicated by the horizontal line, and the error bars represent the SD. (C) Representative fluorescence-activated cell sorter (FACS) plots of a HC
and a GPA patient. IL-10 and IFNg producing Th17 cells are depicted in the upper right corner (blue). Plots are gated on CD3+CD8neg T cells,
30,000 events were acquired for each sample in this gate. *P < 0.05, **P < 0.008.
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appeared similar to those in the HC, and Th17 cells did
not correlate with DN T-cells. Therefore, the nature of
Th17 expansion might be different in SLE when com-
pared to GPA.
We found similar, elevated levels of circulating Th17
cells both in patients with active and quiescent GPA,
implying that there was no association with disease activ-
ity. This is in contrast to findings in SLE and giant cell
arteritis (GCA) where a close relationship of IL-17A+
T cell numbers and disease activity is reported [19,22,41].
Interestingly, IFNg+ T-cells were significantly diminished
during active GPA compared to quiescent GPA, suggest-
ing an inverse association with disease activity. IFNg+
T-cells are found in inflamed lesions in GPA and recruit-
ment from the circulation may therefore explain
the reduction during the active phase of the disease
[10,42-44]. In GCA, steroid therapy during active disease
reduces Th17 cell numbers very efficiently and the reduc-
tion is maintained during remission [19]. Indeed, in our
study a negative association between steroid dose and
Th17 cells was observed, indicating some sensitivity to
steroids. However, in contrast to GCA, a persistent
reduction to normal levels is not achieved in GPA. Th17
cells remained elevated in quiescent GPA patients on
maintenance therapy, and even more so in GPA patients
in whom maintenance therapy was previously withdrawn.
This might have implications for the disease course.
There is circumstantial evidence that persistent Th17
expansion is associated with a higher tendency to relapse.
In a study by Nogueira et al., five patients were prospec-
tively followed, of whom two showed elevated IL-17A
serum levels after remission was achieved. Only those
two patients relapsed within 15 months after first presen-
tation, whereas the other three remained in remission
(follow-up time 15, 20 and 23 months) [24]. In our study,
however, we could not link Th17 expansion to relapse
propensity.
The skewing towards Th17 was not sufficiently
balanced by CD4+CD25highCD127low or IL-10-producing
Tregs. A disturbed balance of pro-inflammatory and
anti-inflammatory T cell subsets with a shift towards
pro-inflammatory subsets is suggested to be an important
pathogenic mechanism of autoimmunity [45]. Accord-
ingly, the observed shift of the Th17/Treg ratio in GPA
might point to an increased risk for exaggerated immune
responses in case of trigger events such as infections [46].
Indeed, infections may provoke relapses in patients with
GPA [47,48]. To a certain extent, patients on mainte-
nance therapy showed a normalization of the Th17/Treg
ratio.
We detected an increased fraction of IL-17+IFNg+ and
IL17+IL-10+ T cells in GPA. IL-17+IFNg+ are described
in human studies as a very potent pro-inflammatory
T cell subset with enhanced migratory capacity [49-51].
Thus, IL-17+IFNg+ might have a role in tissue inflamma-
tion in GPA. Moreover, it is known that T cells have the
capacity to convert into other T cell lineages [50,52].
Plasticity of Th17 and Treg might be an important factor
in autoimmune diseases [53]. Protective Treg converting
into harmful Th17 cells could promote pro-inflammatory
conditions and be fatal for immune homeostasis [54].
Plasticity is a transient, dynamic process and double-
positive IL-17+IL-10+ T cells can be found temporarily
during conversion as part of this process [53]. The exact
role and significance of these Th17 subsets remains to be
studied. [21,49,50,53].
In conclusion, we provide evidence for a persistent,
unbalanced expansion of Th17 cells and Th17 cell sub-
sets which is partly reversed by maintenance therapy in
GPA. Our findings may indicate a pathogenic role of
Th17 cells in GPA.
Conclusions
Th17 cells and Th17 subsets are expanded in GPA irre-
spective of disease activity. Furthermore, the balance of
Th17 cells and Tregs seems to be disturbed. Maintenance
therapy does not normalize Th17 expansion, which per-
sists after therapy is ceased. The significance of Th17
subsets producing IFNg and/or IL-10 should be studied
further.
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